Background: Heart failure with reduced ejection fraction (HFrEF) is a leading cause of cardiovascular mortality and morbidity worldwide. Optimized pharmacological therapy — comprising the four pillars of neurohormonal blockade (ACE inhibitors/ARBs, beta-blockers, MRA, SGLT2i) — h...
Open access
Research Article10.9734/ca/2026/v15i2545
Introduction: Heart failure with reduced ejection fraction (HFrEF), defined as LVEF ≤ 40%, is a major public health problem due to its high morbidity and mortality, affecting approximately 64.3 million individuals worldwide, of whom nearly 50% present with reduced ejection fracti...
Open access
Research Article10.9734/ajcr/2026/v9i1368
Background: Heart failure with reduced ejection fraction (HFrEF) represents a growing global public health burden, particularly in low- and middle-income countries where cardiovascular risk factors are prevalent and undercontrolled. Data from North Africa and Morocco remain scarc...
Open access
Research Article10.9734/ca/2026/v15i2542
Background: The etiological distribution of heart failure with reduced ejection fraction (HFrEF) varies significantly across regions, reflecting differences in cardiovascular risk factor prevalence, genetic predisposition, and healthcare access. Data from North African military p...
Open access
Research Article10.9734/ca/2026/v15i2543
Background: Short-term outcomes in HFrEF, including in-hospital mortality and 30-day rehospitalization, reflect the quality of acute care and the adequacy of discharge management. Data from North African settings remain scarce. Aim: The study aims to evaluate in-hospital outcomes...
Open access
Research Article10.9734/ajcr/2026/v9i1366
Background: Acute rheumatic fever remains an important cause of acquired valvular heart disease where rheumatic heart disease persists in practice, with possible long-term consequences including severe valvular involvement, chamber remodelling, rhythm disturbances, and surgery. O...
Open access
Research Article10.9734/ca/2026/v15i3552